Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page’s revision label was updated from version v3.5.0 to v3.5.3.
    Difference
    0.0%
    Check dated 2026-04-27T08:01:15.000Z thumbnail image
  2. Check
    17 days ago
    No Change Detected
  3. Check
    38 days ago
    Change Detected
    Summary
    Added Revision: v3.5.0 and removed Revision: v3.4.3 on the page.
    Difference
    0.0%
    Check dated 2026-03-22T08:57:14.000Z thumbnail image
  4. Check
    53 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-08T01:55:10.000Z thumbnail image
  5. Check
    67 days ago
    Change Detected
    Summary
    Plain Language Summary added to the Study Details page. The update also lists recent change dates (2026-02-17, 2026-02, 2026-02-19) alongside the new content.
    Difference
    0.1%
    Check dated 2026-02-21T11:04:49.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    The page shows a revision update from v3.4.1 to v3.4.2; this is a minor metadata update with no user-facing impact. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-14T08:57:31.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    Revision: v3.4.1 was added in place of v3.4.0. No other changes to page content are visible. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-07T05:51:31.000Z thumbnail image

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.